CA-SCIENTIST.COM
2.12.2020 10:35:04 CET | Business Wire | Press release
Scientist.com, the healthcare industry’s leading marketplace for outsourced research, has partnered with Enhancing Quality In Preclinical Data (EQIPD) to help define and improve data quality within preclinical research. A self-certification questionnaire is now accessible via Scientist.com’s award-winning compliance solution COMPLi®, allowing global suppliers to self-certify prior to working with biopharma research organizations. With this self-certification, suppliers demonstrate their data integrity processes and procedures to potential clients.
“EQIPD’s holistic approach to tackling the challenges related to data quality within preclinical research aligns with our COMPLi standards, which provides researchers with the proper due diligence necessary to source from suppliers of preclinical services,” stated Matt McLoughlin, VP of Categories & Compliance. “We are working with EQIPD to ensure data integrity is at the heart of research.”
Currently, there are no globally accepted quality standards when it comes to reporting data generated by preclinical research. To define and implement such standards EQIPD has formed a consortium of key stakeholders that includes large pharma (including a number of current Scientist.com clients), biotech companies, academia and compliance solutions. The consortium works closely with Stakeholder Group members such as Scientist.com. EQIPD is looking to develop best practices that can be shared across R&D in the life sciences.
“Use of the EQIPD-derived tools by stakeholders such as Scientist.com enables EQIPD to deliver its mission of improving data integrity standards across the global research community,” stated Anton Bespalov of PAASP, an EQIPD consortium member. “Their COMPLi platform can increase visibility to our work and ensure it aligns completely with the goals of EQIPD moving forward.”
“Including a self-certification questionnaire, based on the EQIPD standard, within COMPLi, streamlines and harmonises the data quality and data integrity due diligence process applied by biopharma research organizations during the on-boarding of preclinical service suppliers,” stated Sandrine Bongiovanni of Novartis Pharma AG.
Research organizations looking to self-certify or learn more about COMPLi can visit https://www.scientist.com/compli/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk, and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies, the Biotechnology Innovation Organization (BIO), and the US National Institutes of Health (NIH).
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook , and Instagram
About EQIPD
The Enhancing Quality in Preclinical Data consortium (EQIPD; previously "European Quality in Preclinical Data") was founded in 2017 by 29 academic institutions, pharmaceutical companies, and SMEs from 8 countries (https://quality-preclinical-data.eu ).
Supported through the European Union’s Innovative Medicines Initiative (IMI), major deliverables of the EQIPD consortium were the development of a novel preclinical research quality system that could be applied in both the public and private sectors, and the generation of online training capacity in good research practice.
The consortium works closely with a large group of associated collaborators, advisors and stakeholders drawn from nearly 100 organizations in Europe and the US and including research institutions, publishers, funders, learned societies and professional societies.
Follow EQIPD on social media:
https://www.facebook.com/EQIPD/
https://twitter.com/EQIPD
https://www.linkedin.com/groups/12074241/profile
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005416/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom